{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:34:28Z","timestamp":1787564068466,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.therap.2023.03.004","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T20:49:06Z","timestamp":1678394946000},"page":"711-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Reality of drug-induced erythema multiforme: A French pharmacovigilance study"],"prefix":"10.1016","volume":"78","author":[{"given":"Sarah","family":"Demouche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bettuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Laugier Castellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Noelle","family":"Osmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Ingen-Housz-Oro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.03.004_bib0100","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cden.2013.07.001","article-title":"Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment","volume":"57","author":"Samim","year":"2013","journal-title":"Dent Clin North Am"},{"key":"10.1016\/j.therap.2023.03.004_bib0105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0190-9622(83)80003-6","article-title":"Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes","volume":"8","author":"Clark Huff","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.03.004_bib0110","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jaad.2019.02.057","article-title":"Triggers, clinical manifestations, and management of pediatric erythema multiforme: a systematic review","volume":"81","author":"Zoghaib","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.03.004_bib0115","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3844\/ajidsp.2008.224.231","article-title":"Erythema multiforme minor: a revision","volume":"4","author":"Oliveira","year":"2008","journal-title":"Am J Infect Dis"},{"key":"10.1016\/j.therap.2023.03.004_bib0120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.03.004_bib0125","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Severe cutaneous adverse reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.therap.2023.03.004_bib0130","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.03.004_bib0135","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaad.2018.03.013","article-title":"Clinical and histologic features of Mycoplasma pneumoniae \u2013related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes","volume":"79","author":"Amode","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.03.004_bib0140","first-page":"37","article-title":"L\u2019organisation de la pharmacovigilance en France, en Europe et dans le monde: de l\u2019AMM \u00e0 l\u2019utilisation d\u2019un traitement innovant: quel parcours\u00a0! (3)","volume":"35","author":"Lebrun-Vignes","year":"2019","journal-title":"Med Sci"},{"key":"10.1016\/j.therap.2023.03.004_bib0145","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2515\/therapie\/2011073","article-title":"R\u00e9actualisation de la m\u00e9thode fran\u00e7aise d\u2019imputabilit\u00e9 des effets ind\u00e9sirables des m\u00e9dicaments","volume":"66","author":"Arimone","year":"2011","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.03.004_bib0150","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2023.03.004_bib0155","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaad.2020.10.091","article-title":"Changing spectrum of suspected drugs of Epidermal Necrolysis: an WHO pharmacovigilance database analysis from 1997 to 2020","volume":"85","author":"Bettuzzi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.03.004_bib0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.therap.2023.03.004_bib0165","doi-asserted-by":"crossref","first-page":"j3817","DOI":"10.1136\/bmj.j3817","article-title":"The diagnosis is in the rings","volume":"359","author":"Ingen-Housz-Oro","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.03.004_bib0170","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/pds.5399","article-title":"Biases associated with epidermal necrolysis reporting in pharmacovigilance: an exploratory analysis using World Health Organization VigiBase","volume":"31","author":"Bettuzzi","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2023.03.004_bib0175","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bcp.13445","article-title":"Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database","volume":"84","author":"Lebrun-Vignes","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.03.004_bib0180","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.03.004_bib0185","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.therap.2023.03.004_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2022.07.008","article-title":"Skin testing and drug provocation tests in epidermal necrolysis: a French experience","volume":"10","author":"Roux","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723000525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723000525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:33Z","timestamp":1758567333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723000525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0040595723000525"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.03.004","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.166576687.74055151\/v1","asserted-by":"object"}]},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reality of drug-induced erythema multiforme: A French pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}